Retinal vein occlusion (RVO) is a common clinical disease in ophthalmology. In recent years, with the emergence of drugs such as anti-vascular endothelial growth factor drugs and sustained release of intraocular glucocorticoids, the therapeutic effect and prognosis of RVO patients have been significantly improved. Nevertheless, in different regions and hospitals at all levels in China, the diagnosis and treatment strategies for RVO are mostly based on their own accumulated experience, and there is still room for improvement in the awareness of ophthalmologists on early intervention of RVO and the popularity of related knowledge, and a set of standardized clinical diagnosis and treatment paths is urgently needed. To this end, Fundus Diseases Group in Ophthalmology Branch of Chinese Medical Association, Professional Committee of Fundus Diseases in Ophthalmology Branch of Chinese Medical Doctor Association through systematic and in-depth literature research and analysis of the latest clinical research results, and combined with the current social and economic development of China, jointly drafted the draft of Expert consensus on clinical diagnosis and treatment path of retinal vein occlusion in China. After several reviews and revisions by the core expert group, the consensus was finalized. This consensus is elaborated in terms of the definition and classification of RVO, etiology and pathogenesis, initial diagnosis and treatment path consensus, and follow-up diagnosis and treatment assessment and follow-up management, aiming to provide easy to understand and grasp practical guidance for ophthalmic specialists and general ophthalmology practitioners. This consensus strictly follows the basic principles of evidence-based medicine, fully considers China's national conditions and existing diagnosis and treatment conditions, and puts forward principled recommendations with general guiding significance for the clinical diagnosis and treatment practice of RVO, aiming to meet the diagnosis and treatment needs of most patients. When applying this consensus to guide practice, clinicians should take into account the specific disease characteristics of patients, combined with various factors such as available treatment means and patients' economic status, and implement individualized comprehensive treatment plans, so as to meet the diversified diagnosis and treatment needs of the majority of RVO patients.
Pathological myopic tractional maculopathy (MTM), as an important type of macular lesions associated with high myopia, play a significant role in the prevention and treatment of myopic macular diseases. With the rapid development of retinal imaging technologies, especially the widespread application of optical coherence tomography, new technical support has been provided for the accurate diagnosis, clinical staging, treatment decision-making, and long-term follow-up of MTM. However, in clinical practice in China, there are still issues such as unclear definitions, inconsistent staging criteria, and significant differences in treatment strategies. To address these challenges, Fundus Diseases Group in Ophthalmology Branch of Chinese Medical Association and Professional Committee of Fundus Diseases in Ophthalmology Branch of Chinese Medical Doctor Association for Ophthalmologists jointly drafted the Expert consensus on management of pathologic myopic tractional maculopathy in China, based on a systematic literature review and the latest clinical evidence. The consensus was revised multiple times by the core expert group and finally finalized. This consensus systematically establishes a standardized diagnostic and therapeutic system for MTM, covering disease definition and staging, diagnostic pathways and follow-up protocols, treatment strategies based on staging, and surgical intervention plans. It aims to provide ophthalmologists at all levels with a scientifically sound and practically applicable clinical guidance. The development of the consensus strictly adheres to the principles of evidence-based medicine, fully considering the actual clinical conditions of medical institutions at different levels in China. It provides principled recommendations with broad guiding significance for the clinical practice of MTM. It is particularly emphasized that when applying this consensus, clinicians should comprehensively consider the patient’s clinical characteristics, treatment accessibility, and socioeconomic factors, and implement personalized and precise treatment strategies to meet the diverse clinical needs of patients with pathological myopia.